Advanced Cancers Clinical Trial
Official title:
The Influence of Patients' Knowledge, Attitudes and Beliefs on Self Reported Deviations From Opioid Analgesic Prescription: an Exploratory Survey
Primary Objective:
1. To determine the frequency of self-reported over and under use of opioid analgesics in
patients with advanced cancer. Patients with advanced cancer are those patients who
have been described to have either one of the following: recurrent disease, those that
have failed multiple chemotherapies (more than second line therapy), locally advanced
disease, and metastatic disease.
Secondary Objectives:
1. To determine the association between patients' knowledge, attitudes and beliefs about
opioids, and frequency of deviation in opioid use with patients' demographic
information.
2. To determine association between alcohol abuse/chemical coping and self-reported
deviations in opioid use.
3. To determine the association between the use of opioids and patient-related barriers to
opioid use.
Screening:
Before you start the study, the research nurse will check your medical record to see if you
are eligible to take part in this study. Information will be recorded about your
demographics (such as age, marital status, ethnicity, education level, and gender), medical
history (such as the type of cancer and level of pain), and prescriptions (such as the name
of any opioid drugs, doses, and schedule).
Interview Process:
If you are found to be eligible to take part in this study, you will be interviewed by the
study staff before a regular visit with your doctor. You will be asked some questions about
your use of pain drugs and other knowledge and/or attitudes that you may have about them.
You may also be asked for general information (such as your age, marital status, or
educational level) if it was not available in your chart and medical record.
Questionnaires:
After the interview, you will complete 5 short questionnaires about your use of pain drugs,
your attitudes about the pain drugs and their use, and concerns that you may have about your
use of these pain drugs.
It will take about 5-10 minutes for the interview and another 10-15 minutes to complete all
the questionnaires.
Your interview and questionnaire responses will not be shared with your regular doctor
unless the study staff feels that you maybe be at harm. If you feel you need a doctor's
opinion about anything that is asked in the interview and/or questionnaires, please contact
your doctor.
Confidentiality:
Your interview and questionnaire responses will only be used for this research study and
will not be shared with your family members.
Length of Study:
After completing the interview and questionnaires, your participation in this study will be
over.
This is an investigational study. Up to 200 patients will take part in this study. All will
be enrolled at M. D. Anderson.
;
Observational Model: Case-Only, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01213238 -
Hepatic Arterial Infusion Oxaliplatin, Capecitabine With or Without Bevacizumab
|
Phase 1 | |
Recruiting |
NCT02160366 -
Profile Related Evidence to Determine Individualized Cancer Therapy (PREDICT) Program in Advanced Cancer Patients
|
||
Completed |
NCT00903708 -
LY2275796 in Advanced Cancer
|
Phase 1 | |
Completed |
NCT00379353 -
The Effects of Thalidomide on Symptom Clusters
|
Phase 2 | |
Terminated |
NCT00499382 -
Quantitation of Left Ventricular Ejection Fraction as Part of F-18 FDG Whole Body PET/CT Scans For Tumor Staging
|
N/A | |
Completed |
NCT02459964 -
Compare Fentanyl Nasal Spray With Intravenous Opioids to Treat Severe Pain
|
Phase 4 | |
Completed |
NCT01430572 -
Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss Patients
|
Phase 1 | |
Completed |
NCT02561234 -
A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT01375114 -
The Effects of Ginseng on Cancer-Related Fatigue
|
Phase 2 | |
Completed |
NCT01201694 -
Phase I Study of Surface-Controlled Water Soluble Curcumin (THERACURMIN CR-011L)
|
Phase 1 | |
Completed |
NCT01454804 -
Pazopanib, Lapatinib or Trastuzumab in Subjects With Solid Tumors
|
Phase 1 | |
Completed |
NCT02801045 -
Art Therapy in Palliative Care: Study of Identification and Understanding of the Mechanisms of Change in the Patient
|
N/A | |
Completed |
NCT02873975 -
A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency
|
Phase 2 | |
Completed |
NCT01983969 -
Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma
|
Phase 1/Phase 2 | |
Completed |
NCT02272595 -
Rational Therapeutics Based on Matched Tumor and Normal Tissue
|
||
Active, not recruiting |
NCT01999491 -
A Phase 1 Dose-Escalation and Pharmacokinetic Study of NC-4016 in Patients With Advanced Solid Tumors or Lymphoma
|
Phase 1 | |
Recruiting |
NCT03375983 -
Plasmodium Immunotherapy for Advanced Cancers
|
Phase 1/Phase 2 | |
Completed |
NCT02571036 -
A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies
|
Phase 1 | |
Withdrawn |
NCT01608139 -
Study of Curcumin, Vorinostat, and Sorafenib
|
Phase 1 | |
Completed |
NCT01024166 -
Patient-Reported Outcomes-Based Palliative and Hospice Care Practice: A Usability Study
|
N/A |